A new molecular engineering method, termed TAC-seq, has been developed to enhance the precision of clinical biomarker analysis.
Take a look at our overview of the top events in the world of bioanalysis for January, February and March 2019.
Bristol-Myers Squibb (NY, USA) have announced that they will be acquiring Celgene (NJ, USA) this year for a cost of $74 billion.
Want to find out what happened last year? Editor, Lucy Cliff, highlights the best of 2018’s bioanalytical research in an A–Z round-up.
A small implantable device using LEDs has been developed to treat bladder problems, with the potential to replace current medications and electronic stimulators.
Find out more about the latest news in cardiovascular research including the development of disease biomarkers and cardiomyocyte sensors in this round-up.
Researchers from McMaster University (Ontario, Canada) have discovered several new biomarkers that could allow earlier detection of cystic fibrosis from a single drop of blood.
A noninvasive skin-stripping test has been developed to differentiate between eczema and psoriasis when diagnosing inflammatory skin diseases.
Researchers from Syracuse University (NY, USA) have developed a novel class of nanobiosensor that could detect, characterize and analyze protein–protein interactions in blood serum to assist in cancer detection.
Thermo Fisher Scientific (MA, USA) have announced the launch of a new complementary diagnostic immunoassay, the Thermo Scientific QMS Plazomicin Immunoassay, for measuring the concentration of a novel therapeutic antibiotic, plazomicin, used to treat complicated urinary tract infections.